CoChat

The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE −/− mouse model

Gaspari, Tracey, Welungoda, Iresha, Widdop, Robert E, Simpson, Richard W, Dear, Anthony E · 2013 · Diabetes and Vascular Disease Research

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Abstract

Liraglutide, a once-daily glucagon-like peptide-1 receptor (GLP-1R) agonist, has been approved as a new treatment for type 2 diabetes and is the subject of a clinical trial programme to evaluate the effects on cardiovascular disease and safety. The current study aimed to determine the in vivo effect of liraglutide on progression of atherosclerotic vascular disease in the apolipoprotein E-deficient (ApoE −/− ) mouse model and identify underlying mechanisms responsible. Liraglutide treatment inhibited progression of early onset, low-burden atherosclerotic disease in a partially GLP-1R-dependent manner in the ApoE −/− mouse model. In addition, liraglutide treatment inhibited progression of atherosclerotic plaque formation and enhanced plaque stability, again in a partially GLP-1R-dependent manner. No significant effect of liraglutide on progression of late onset, high-burden atherosclerotic disease was observed. In addition, no significant endothelial cell dysfunction was identified in ApoE −/− mice with early onset, low-burden atherosclerotic disease, although significant prevention of weight gain was observed in liraglutide-treated mice using this dietary protocol. Taken together, these results suggest a potential role for liraglutide in the prevention and stabilisation of atherosclerotic vascular disease together with possible protection against major cardiovascular events.

Overview

Integrity signals

Registry

Crossref · 10.1177/1479164113481817

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

1 retracted

Cited by

See all 155

Metadata

Authors
Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E.
Affiliations
  • Monash University (AU)
  • Eastern Health (AU)
Venue
Diabetes and Vascular Disease Research
Published
2013-05-14
Volume
10
Issue
4
Pages
353-360
ISSN
  • 1479-1641 (ISSN-L)
  • 1752-8984
OpenAlex
W2097575918
Cited by
148
References
32
Citations by year
2026: 11 · 2025: 16 · 2024: 11 · 2023: 7 · 2022: 19 · 2021: 14 · 2020: 6 · 2019: 18 · 2018: 9 · 2017: 9 · 2016: 12 · 2015: 7 · 2014: 7 · 2013: 2
FWCI
7.34
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Diabetes and Vascular Disease Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
liraglutide, GLP-1 receptor agonists, atherosclerosis, atherosclerotic plaque stability, endothelial function, ApoE-deficient mice, cardiovascular disease prevention, weight gain, type 2 diabetes
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Apolipoproteins E, Diabetes Mellitus, Type 2, Disease Models, Animal, Hypoglycemic Agents, Mice, Inbred C57BL, Receptors, Glucagon, Mice, Knockout, Disease Progression, Endothelial Cells, Atherosclerosis, Mice, Glucagon-Like Peptide 1, Plaque, Atherosclerotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.